Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GBA to decide on future of Merck's ezetimibe after German assessment sees no benefit

This article was originally published in Scrip

Executive Summary

IQWiG, Germany's Institute for Quality and Efficacy in Healthcare, says that the benefits of the hypolipidaemic combination product ezetimibe are not clear. The institute's report does not bode well for Merck & Co, which markets Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin). The company must not await the verdict of the GBA, the Federal Joint Committee, which makes decisions on reimbursement, whether or not to take action on the report. It "undermines the drug and adds weight to the argument that it should not be prescribed so widely," says Gideon Heap, an analyst at Datamonitor.

You may also be interested in...



Canada Counters Drug Shortages With Export Bans

Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.

The COVID-19 Economic Crisis – Fallout And Opportunities

In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Topics

Related Companies

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel